Systems biology, information, disease and drug discovery

Drug Discovery World

Volumn 6, Issue 1, 2004, Pages 23-33

  Naylor, Stephen ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E3; NEW DRUG; PROTEIN;

ARTICLE; ATHEROSCLEROSIS; BIOLOGY; BIOTECHNOLOGY; CELL ORGANELLE; DATA ANALYSIS; DECISION MAKING; DISEASE MODEL; DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; GENOMICS; HUMAN; HYPERLIPOPROTEINEMIA; INFORMATION PROCESSING; MOUSE; NONHUMAN; SIMULATION; VALIDATION PROCESS;

EID: 14044260054     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Tufts University, Tufts Center for the Study of Drug Development. http://csdd.tufts.edu/InfoServices/Publications.asp.2004
2. Booth, B and Zemmel, R. Prospects for productivity. Nat. Rev. Drug Dis. 3: 451-456 (2004).
3. Anonymous. Parexels Pharmaceutical R & D Statistical Sourcebook 2003/2004. page 42. (Parexels International Corporation, Waltham, MA, USA 2003).
4. Bains, W. Failure rates in drug discovery and development: will we ever get any better? Drug Discovery World 5: 9-18 (2004).
5. Hood, L. A personal view of molecular technology and how it has changed biology. J. Protome Res. 1: 399-409 (2002).
6. Ideker, T et al. Integrated genomic and proteomic analysis of a systematically perturbed metabolic network. Science 292: 929-934 (2001).
7. Naylor, S and Kumar, R. Emerging role of mass spectrometry in structural and functional proteomics. Adv. Protein Chem. 265: 217-235 (2003).
8. Morel, N et al. Introduction to systems biology - A new approach to understanding disease and treatment. Mayo Clin. Proc. 79: 651-658 (2004).
9. Editorial, End of the interlude? Nat. Biotech. 22: 1191 (2004).
10. Kitano, H. Foundations of Systems Biology (2001). MIT Press, Cambridge, USA.
11. Kitano, H. Computational systems biology. Nature 420: 206-210 (2002).
12. Nicholson, JK et al. The challenges of modeling mammalian biocomplexity. Nat. Biotech. 22: 1268-1274 (2004).
13. Clish, C et al. Integrative Biological Analysis of the APOE*3 Transgenic Mouse. OMICS. J. Integrative Biol. 8: 3-13 (2004).
14. Stephanopoulos, G et al. Exploiting biological complexity for strain improvement through systems biology. Nat. Biotech. 22: 1261-1267 (2004).
15. Rubenstein, K. Systems Biology: Key to Unlocking the Value Within the Omics Revolution. (2004) DM&D Publications, Westborough, MA, USA (http://www.drugandmarket.com).
16. Butcher, EC et al. Systems biology in drug discovery. Nat. Biotech. 22: 1253-1259 (2004).
17. Wiener, N. Cybernetics or Control Communication in the Animal and the Machine. (1965), MIT Press, Cambridge, MA, USA.
18. von Bertalanffy, L. General Systems Theory, (1969), Braziller, New York, USA.
19. Viot, EO. Computational Analysis of Biochemical Systems - A Practical Guide for Biochemists and Molecular Biologists. (2000) Cambridge University Press, Cambridge, UK.
20. Heinrich, R and Schuster, S. The Regulation of Cellular Systems. (1996), Chapman & Hall, New York, USA.
21. Mack, GS. Can complexity be commercialized? Nat. Biotech. 22: 1223-1229 (2004).
22. Weston, A.D and Hood, L. Systems biology, proteomics and the future of healthcare: toward predictive, preventive and personalized medicine. J. Proteome Res., 3: 179-196 (2004).
23. Naylor, S and Cavanagh, J. Status of systems biology-does it have a future? Drug Discovery Today-Biosilico 2: 171-174 (2004).
24. Hood, L and Perlmutter, RM. The impact of systems approaches on biological problems in drug discovery. Nat. Biotech. 22: 1215-1217 (2004).
25. Marinissen, MJ and Gutkind, JS. G-Protein-Coupled Receptors and Signaling Networks: Emerging Paradigms. Trends Pharmacol. Sci. 22: 368-376 (2001).
26. Hopkins, AL and Groom, CR. The Druggable Genome. Nat Rev. Drug Discov. 1: 727-732 (2002).
27. Terret, NK et al. Sildenafil (Viagra ™ ), a Potent and Selective Inhibitor of Type 5 cGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction . Bioorg. Med. Chem. Lett. 6: 1819-1825 (1996).
28. Capdeville, R et al. Glivec (ST1571, Imatinib), a Rationally Developed, Targeted Anticancer Drug. Nat. Rev. Drug Discov. 1: 493-499 (2002).
29. Alm, E and Arkin, AP. Biological networks. Curr. Opin. Struct. Biol. 13: 193-204 (2003).